No Data
Eli Lilly to Expand Two Ireland Sites With $1.8 Billion Investment
Express News | Eli Lilly: Ebglyss Will Be Available in United States in Coming Weeks
Express News | FDA Approves Lilly's Ebglyss™ (Lebrikizumab-Lbkz) for Adults and Children 12 Years and Older With Moderate-to-Severe Atopic Dermatitis
Eli Lilly Analyst Ratings
Bullish on the future of the "weight-loss miracle drug" Tesofensine, Citigroup reinitiates coverage of eli lilly and co (LLY.US) with a "buy" rating.
Citigroup rates Eli Lilly and Co (LLY.US) as 'buy' with a target price of $1060.
BofA Securities Initiates Eli Lilly and Co(LLY.US) With Buy Rating